We are live on ! Find out more
HMC

Harvard Management Company Portfolio holdings

AUM $1.82B
1-Year Est. Return 26.23%
This Fund
S&P 500
This Quarter Est. Return
+28.13%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$952M
AUM Growth
+$145M
Cap. Flow
-$15.2M
Cap. Flow %
-1.6%
Top 10 Hldgs %
83.36%
Holding
48
New
2
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$1.04M
2
LOCO icon
El Pollo Loco
LOCO
+$514K

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$8.74M
2
PLRX icon
Pliant Therapeutics
PLRX
+$8.01M

Sector Composition

Rank Sector Weight
1 Communication Services 51.57%
2 Consumer Discretionary 16.94%
3 Technology 16.01%
4 Healthcare 11.54%
5 Industrials 2.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNTE
26
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.11M 0.33%
498,001
– –
VIGL
27
DELISTED
Vigil Neuroscience
VIGL
$2.83M 0.3%
289,460
– –
TNGX icon
28
Tango Therapeutics
TNGX
$4.72B
$2.8M 0.29%
708,385
– –
NRIX icon
29
Nurix Therapeutics
NRIX
$2.62B
$2.8M 0.29%
314,762
– –
PACB icon
30
Pacific Biosciences
PACB
$363M
$2.65M 0.28%
229,144
– –
GBIO
31
DELISTED
Generation Bio
GBIO
$2.19M 0.23%
51,035
– –
PCTTW
32
PureCycle Technologies Inc Warrant
PCTTW
$2.19M 0.23%
714,285
– –
AFRM icon
33
Affirm
AFRM
$25.6B
$1.96M 0.21%
173,560
– –
TNYA icon
34
Tenaya Therapeutics
TNYA
$157M
$1.92M 0.2%
673,270
– –
SANA icon
35
Sana Biotechnology
SANA
$949M
$1.53M 0.16%
468,749
– –
KITT icon
36
Nauticus Robotics
KITT
$7.32M
$1.49M 0.16%
193
– –
XLO icon
37
Xilio Therapeutics
XLO
$61M
$1.32M 0.14%
29,719
– –
DYN icon
38
Dyne Therapeutics
DYN
$4.83B
$1.24M 0.13%
107,252
– –
PATH icon
39
UiPath
PATH
$7.25B
$1.21M 0.13%
+69,073
New +$1.04M
FULC icon
40
Fulcrum Therapeutics
FULC
$288M
$1.17M 0.12%
410,714
– –
DBTX
41
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$993K 0.1%
328,798
– –
MCRB icon
42
Seres Therapeutics
MCRB
$47.9M
$748K 0.08%
6,592
– –
PRAX icon
43
Praxis Precision Medicines
PRAX
$10.3B
$630K 0.07%
51,901
– –
IRON icon
44
Disc Medicine
IRON
$2.97B
$530K 0.06%
25,000
– –
PRDS
45
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$528K 0.06%
400,000
– –
SRZN icon
46
Surrozen
SRZN
$251M
$498K 0.05%
55,123
– –
LOCO icon
47
El Pollo Loco
LOCO
$499M
$433K 0.05%
+45,188
New +$514K
DNTH icon
48
Dianthus Therapeutics
DNTH
$6.15B
$264K 0.03%
20,788
– –
1
2

Similar funds

DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $1.82B AUM 19.69% 1-Year Est. Return
SI
Standard Investments New York $1.83B AUM 4.12% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
KAM
Kensington Asset Management Austin, Texas $1.84B AUM 13.95% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

Harvard Management Company's Q1 2023 Portfolio in Review

As of Q1 2023, Harvard Management Company held 48 positions worth $952M, up 18% from $807M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 4.2%. Harvard Management Company opened 2 new positions and made no exits, leaving the 48-position portfolio largely intact.

By sector, the portfolio is most concentrated in Communication Services at 52% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Harvard Management Company's largest Q1 2023 buy was UiPath: 69,073 shares worth $1.21M.
  • Harvard Management Company's biggest Q1 2023 reduction was Revolution Medicines, cutting an estimated $8.74M.
  • Harvard Management Company's ten largest holdings make up 83% of its $952M portfolio in Q1 2023.
  • Harvard Management Company opened 2 new positions and closed 0 in Q1 2023.
  • Harvard Management Company's portfolio value rose 18% quarter-over-quarter to $952M.

Based on Harvard Management Company's 13F filing for Q1 2023, filed 15 May 2023.